These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 32986983)

  • 1. Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world.
    Zhang N; Tan J; Yang H; Khalil RA
    Biochem Pharmacol; 2020 Dec; 182():114247. PubMed ID: 32986983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do knowledge of uterine artery resistance in the second trimester and targeted surveillance improve maternal and perinatal outcome? UTOPIA study: a randomized controlled trial.
    García B; Llurba E; Valle L; Gómez-Roig MD; Juan M; Pérez-Matos C; Fernández M; García-Hernández JA; Alijotas-Reig J; Higueras MT; Calero I; Goya M; Pérez-Hoyos S; Carreras E; Cabero L
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):680-9. PubMed ID: 26823208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
    Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
    Am J Obstet Gynecol; 2021 May; 224(5):518.e1-518.e11. PubMed ID: 33166504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
    Tsiakkas A; Saiid Y; Wright A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jul; 215(1):87.e1-87.e17. PubMed ID: 26875953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction.
    Crispi F; Llurba E; Domínguez C; Martín-Gallán P; Cabero L; Gratacós E
    Ultrasound Obstet Gynecol; 2008 Mar; 31(3):303-9. PubMed ID: 18058842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
    Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
    J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of placental growth factor and uterine artery doppler pulsatility index in pregnancies involving intrauterine fetal growth restriction or preeclampsia to predict perinatal outcomes.
    Gomez-Roig MD; Mazarico E; Sabria J; Parra J; Oton L; Vela A
    Gynecol Obstet Invest; 2015; 80(2):99-105. PubMed ID: 25924544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.
    Reslan OM; Khalil RA
    Cardiovasc Hematol Agents Med Chem; 2010 Oct; 8(4):204-26. PubMed ID: 20923405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined screening for early and late pre-eclampsia and intrauterine growth restriction by maternal history, uterine artery Doppler, mean arterial pressure and biochemical markers.
    Litwińska E; Litwińska M; Oszukowski P; Szaflik K; Kaczmarek P
    Adv Clin Exp Med; 2017; 26(3):439-448. PubMed ID: 28791818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
    Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
    Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal venous Doppler characteristics are abnormal in pre-eclampsia but not in gestational hypertension.
    Gyselaers W; Staelens A; Mesens T; Tomsin K; Oben J; Vonck S; Verresen L; Molenberghs G
    Ultrasound Obstet Gynecol; 2015 Apr; 45(4):421-6. PubMed ID: 24890401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
    Litwinska M; Syngelaki A; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):365-372. PubMed ID: 29943498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
    Sharabi-Nov A; Kumar K; Fabjan Vodušek V; Premru Sršen T; Tul N; Fabjan T; Meiri H; Nicolaides KH; Osredkar J
    Fetal Diagn Ther; 2020; 47(6):471-484. PubMed ID: 31778996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy.
    Sheppard SJ; Khalil RA
    Cardiovasc Hematol Disord Drug Targets; 2010 Mar; 10(1):33-52. PubMed ID: 20041838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of antenatal care on pregnancy outcome.
    Ekwempu CC
    Trop J Obstet Gynaecol; 1988; 1(1):67-71. PubMed ID: 12179287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome.
    Muñoz-Hernández R; Medrano-Campillo P; Miranda ML; Macher HC; Praena-Fernández JM; Vallejo-Vaz AJ; Dominguez-Simeon MJ; Moreno-Luna R; Stiefel P
    Am J Hypertens; 2017 Jul; 30(7):673-682. PubMed ID: 28338787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.